Clinical Trial Detail

NCT ID NCT02620865
Title Bispecific Antibody Armed Activated T-cells With Aldesleukin and Sargramostim in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer
Recruitment Active, not recruiting
Gender both
Phase Phase Ib/II
Variant Requirements no
Sponsors Barbara Ann Karmanos Cancer Institute
Indications

pancreatic adenocarcinoma

Therapies

Paclitaxel

Aldesleukin

Oxaliplatin

Sargramostim

Gemcitabine

Fluorouracil + Leucovorin

Age Groups: adult

No variant requirements are available.